“I’m thrilled to join this visionary biotech company that could have an enormous impact on medicine,” said Bostock. “The future of medicine is cellular therapy and the GID BIO team is on the cusp of a breakthrough in regenerative medicine to treat significant diseases where there is no current solution.”
As a two-sport athlete at Duke University, Bostock understands the crippling impact a degenerative musculoskeletal disease can have on an active person’s body. He is an advocate for our cellular therapy treatment option and its potential to transform millions of lives and reduce staggering costs accompanying traditional surgery.
Over the last several years, clinical trials have tested our cellular therapy’s safety and efficacy for the treatment of pain and function associated with knee osteoarthritis. In March, American Journal of Sports Medicine published one- and two-year results from a randomized, placebo-controlled Phase IIb clinical trial. In June, WWL-TV announced a pivotal Phase III study which will begin soon at Tulane University School of Medicine, the Texas Center for Cell Therapy and Research in San Antonio and New Jersey Regenerative Institute. Additional sites will be announced soon.
“This is an exciting time at GID. We are relentless in our commitment to advance clinically effective and cost-effective cellular therapies for the benefit of millions,” said William W. Cimino, Ph.D., CEO of GID BIO. “Roy’s range of expertise will be instrumental as we look to the future to complete our pivotal Phase III studies and prepare to bring cellular therapy to market.”